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Abstract
Background: Cardiovascular morbidity and mortality is increased in individuals with severe mental illnesses.
We set out to establish a multicentre, two arm, parallel cluster randomized controlled trial (RCT) of a health
promotion intervention (HPI), IMPACT Therapy. The patient-tailored IMPACT Therapy aims to target one or more
health behaviours from a pre-defined list that includes cannabis use; alcohol use; other substance use; cigarette
smoking; exercise; diet and diabetic control, prioritising those identified as problematic by the patient, taking a
motivational interviewing and CBT approach.
Methods: Impact therapy will be delivered by care coordinators in the community to the treatment group and will
be compared to treatment as usual (TAU). The main hypothesis is that the addition of IMPACT Therapy (HPI) to TAU
will be more effective than TAU alone in improving patients’ quality of life as measured by the Short Form-36,
including mental health and physical health subscales on completion of the intervention at 12 months post
randomisation. A subsidiary hypothesis will be that addition of IMPACT Therapy (HPI) will be more cost-effective
than TAU alone in improving health in people with SMI 12 months from baseline. The IMPACT therapy patient
groups’ improvement in quality of life, as well as its cost effectiveness, is hypothesised to be maintained at
15 months. Outcomes will be analyzed on an intention-to-treat (ITT) basis.
Discussion: The results of the trial will provide information about the effectiveness of the IMPACT therapy
programme in supporting community mental health teams to address physical comorbidity in severe mental illness.
Trial registration: ISRCTN58667926.
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controlled trial
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Background
People with severe mental illnesses (SMI) such as schizo-
phrenia, schizoaffective disorder and bipolar affective dis-
order die up to 20–25 years earlier than the general
population[1-4]. Most of this premature mortality is due
to physical disorders [5,6] with cardiovasular disease [7-9]
and specially prominent. Worryingly, the mortality gap
between those with schizophrenia and the general popula-
tion appears to have widened in recent years [10].
High rates of modifiable cardiovascular disease (CVD)
risk factors are seen in SMI, [11,12] including abdominal
obesity; insulin resistance/glucose intolerance; hyperten-
sion; and dyslipidaemia;[13] these factors increase the
chance of developing complications such as diabetes,
heart disease, stroke, amputation, renal failure, blindness
and ultimately, early death [14-17]. Antipsychotic medi-
cations accelerate weight gain and the onset of diabetes.
[18-21]Once CVD risk factors develop, impaired motiv-
ation in SMI makes implementing lifestyle change chal-
lenging, [22,23] again increasing the risk of complications.
On top of that, episodes of acute psychosis may interrupt
diabetic control.
It is possible to prevent the development of CVD risk
factors in SMI [24] and strategies exist to manage
existing CVD risk [25]. The CATIE study confirmed that
smoking cessation, nutrition counselling and supervised
exercise programmes can help to reduce cardiovascular
mortality in SMI [26], but this can be difficult to insti-
tute in practice. The UK government now emphasises
the importance of health promotion in reducing car-
diovascular disease burden in SMI [27,28]. However,no
health promotion programmes have yet been adequately
demonstrated in the UK to be reliable, reproducible and
workable across the National Health Service (NHS).
To complicate matters, more people with SMI smoke
cigarettes, [29,30] and use cannabis and other illicit
drugs than do the general population [31,32]. On-going
cannabis use leads both to poorer mental and physical
health outcomes [33-37] with cannabis users on psychiatric
intensive care units having higher serum glucose levels and
heavier weights compared to non-cannabis users [38].
More recently developed treatment programmes for people
with both psychosis and substance use show some promise
[39-41] but are lengthy, complex and expensive. In clinical
practice of course, parallel attendance at separate treat-
ment programmes for physical health and drug use is often
impractical.
A more practical alternative to separately addressing
physical health and substance use may be an intervention
targeting both lifestyle and substance use to maximize
physical and mental health. We have developed a modular,
manualised, health promotion intervention, IMPACT
therapy [42], covering physical health, mental health and
substance use, integrating the combined benefits of
motivational interviewing and cognitive behavioural ther-
apy (CBT) approaches at both individual and group level
to effect lifestyle change. [42] This paper describes the
study protocol for the Improving physical health and re-
ducing substance use in Psychosis (IMPACT) randomised
controlled trial (IMPACT RCT) to assess the effectiveness
of IMPACT therapy (i.e. health promotion intervention
(HPI)).
Objectives
The primary objective is to determine the effectiveness and
cost-effectiveness of the addition of an intensive health
promotion intervention (IMPACT Therapy), designed to
improve physical health and reduce substance use, to usual
mental health care delivered by care coordinators (TAU) in
people with severe mental illness (SMI) (defined as schizo-
phrenia (ICD-10 code: F20), delusional Disorder (F22.0),
schizoaffective disorder (F25), bipolar affective disorder
(F31), recurrent depressive disorder (F32), current epi-
sode severe with psychotic symptoms (F33.3)).
The main hypothesis is that the addition of IMPACT
Therapy (HPI) to TAU will be more effective than TAU
alone in improving patients’ quality of life as measured by
the Short Form-36, including mental health and physical
health subscales [43] on completion of the intervention at
12 months post randomisation. This 12 month period in-
corporates an initial 3 months post randomisation to train
the care coordinators to provide the IMPACT Therapy
(HPI) over the following 9 months. We also hypothesise
that the effect will be sustained three months after the end
of the intervention, at 15 month follow up.
Our secondary hypothesis is that the addition of IM-
PACT Therapy (HPI) will be more cost-effective than
TAU alone in improving health in people with SMI
12 months from baseline and that this cost-effectiveness
will be sustained 3 months later at 15-month follow-up.
Subsidiary Hypotheses include
1. TAU plus IMPACT Therapy will reduce waist
circumference by at least 1 cm at one year,
compared to TAU alone
2. TAU plus IMPACT Therapy will be more effective in
reducing weight at one year, compared to TAU alone
3. TAU plus IMPACT Therapy will result in a 50%
reduction in proportion of people using cannabis
compared to TAU alone.
4. TAU plus IMPACT Therapy will be more effective
in reducing symptoms of psychosis compared to
TAU alone
Methods
Design
A multicentre, two arm, parallel cluster randomized con-
trolled trial (RCT) of an health promotion intervention,
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(HPI) IMPACT Therapy. The study was planned and
implemented in concordance with the Consolidated Stan-
dards of Reporting Trials (CONSORT) cluster trial exten-
sion standards [44,45] to compare the cost-effectiveness of
combining treatment as usual (TAU) plus IMPACT Ther-
apy, versus TAU alone in improving health at one-year
follow-up. Figure 1 summarises the trial design.
Setting
The study will take place within community mental
health teams (CMHTs), including continuing care/recov-
ery teams; community rehabilitation; assertive outreach
and community forensic teams in six Mental Health
NHS Trusts in the urban and rural locations of South
London, Sussex, Somerset, Staffordshire and Shropshire.
We will not recruit from specialist first episode psych-
osis teams.
Participants
Care coordinators permanently employed and intending
to remain so for a period of one year within the CMHT
settings above, with a minimum of four patients on their
caseload with a primary diagnosis of SMI, are eligible for
recruitment to the trial.
Patients of participating care co-ordinators are eligible
for inclusion in the study if:
a) Aged between 18–65 years old.
b) A diagnosis of a psychotic disorder (ICD 10
diagnosis F20-29, F31.2, F31.5,)
Exclusion criteria:
a) A primary diagnosis of learning disability.
b) A co-existing physical health problem that would, in
the opinion of the medical investigators,
independently impact on metabolic measures and/or
substance use habits.
c) Current pregnancy, plus mothers less than 6 months
post-partum.
d) Life threatening or terminal medical conditions
where intensive care is already provided.
Pre-randomisation
All care-coordinators in participating CMHTs will be of-
fered best practice treatment as usual training on phys-
ical health awareness, including the provision of health
promotion leaflets on healthy dietary routines and phys-
ical exercise, together with information on general and
community support for a healthy lifestyle. The purpose
of this is to ensure that all care-coordinators, irrespect-
ive of which treatment arm they are allocated to, have
the same baseline level of understanding of physical
health issues, thus ensuring more standardised treatment
as usual.
Selection and randomisation
This is a cluster randomised trial and the randomisation
will take place at the level of the care co-ordinator. To
select the order in which first care co-ordinators and
then patients are approached, a random numbers gener-
ator will be used. Researchers will approach each eligible
care coordinator in this order and seek consent to par-
ticipate in the trial, working down the list until the tar-
get sample size is achieved.
Prior to randomisation, consenting care-coordinators
will provide a list of their current patient caseload. Pa-
tients on that caseload meeting the inclusion criteria will
be entered into the random numbers generator to create
a randomly ordered list in which to approach potential
participants. Researchers will then approach these pa-
tients sequentially and seek informed consent to partici-
pate in the RCT. In situations where a patient does not
wish to take part in the study, the researcher will select
another patient from the list in that random order.
After completing baseline assessments on all consenting
patients in a care co-ordinator’s caseload, the clinical trials
unit will conduct randomisation of the care coordinators,
stratified by borough, using randomisation blocks of ran-
dom sizes to either treatment arm (IMPACT Therapy) or
treatment as usual (TAU).
Researchers and the statistician will remain blind to
treatment allocation. Outcome assessments will only be
conducted by researchers blind to the treatment arm.
Any violations of the study protocol will be recorded
and reported to the Trial Steering Committee and the
Data Monitoring and Ethics Committee.
Intervention: IMPACT therapy
All consenting community care coordinators randomised
to the IMPACT Therapy arm will receive 4-day IMPACT
training on physical health and substance use in SMI, as
well as training in motivational interviewing (MI), cogni-
tive behavioural therapy (CBT) techniques and in running
groups to deliver health promotion. The patient-tailored
IMPACT Therapy aims to target one or more health be-
haviours from a pre-defined list that includes cannabis
use; alcohol use; other substance use; cigarette smoking;
exercise; diet and diabetic control, prioritising those iden-
tified as problematic by the patient, taking a MI and CBT
approach. Participants may start the community-based
IMPACT Therapy as soon as they are well enough to at-
tend, even if they are in-patients, to mirror clinical prac-
tice. IMPACT Therapy is supported by a manual, a
reference book and a service user handbook [46]. Each
care coordinator in the active intervention arm of the
study will receive copies of these books.
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Care coordinators Assessed for eligibility (n=  )
Excluded  (n=   )
Declined to participate (n=  )
Lost to follow-up (give reasons) 
Number of care coordinators
Allocated to intervention plus TAU (
Number of care coordinators
Number of patients
Allocated to TAU (n=  )
Number of care coordinators
Number of patients
Allocation
Care coordinators consented (n=  )
Enrollment
Patients Assessed for eligibility (n=  )
Care coordiators  Randomised (n=  )
Excluded  (n=   )
Not meeting inclusion criteria (n=  )
Analysed  (n=  )
Excluded from analysis (give reasons) (n=  )
Analysed  (n=  )
Excluded from analysis (give reasons) (n=  )
Lost to follow-up (give reasons) 
Number of care coordinators
Lost to follow-up (give reasons) 
Number of care coordinators
Lost to follow-up (give reasons) 
Number of care coordinators
Analysis
Follow-Up 
15months
Follow-Up 12 
months
Declined to participate (n=  )
Figure 1 Summary of Trial design for Improving Physical health and reducing substance use in Psychosis – Randomised Control Trial
(IMPACT RCT): Study protocol.
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Care Coordinators allocated to the IMPACT Therapy
arm of the trial will also receive supervision every
2 weeks to ensure fidelity of the intervention and to pro-
vide ongoing support and training. The supervision will
be provided by research therapists by face-to-face con-
tact, via video link or via Skype, supplemented by e-mail
and/or telephone support.
Patients participating in the IMPACT therapy arm will
have the option to receive three-monthly newsletters
throughout the trial period (total of 4), each providing
tips on healthy living. The information contained in the
newsletter will comprise standard information that is
readily available to the public.
Outcome measures
Outcomes will be measured by self-report, objective as-
sessments and face-to-face interviews. All participants
will be assessed at the following time points: baseline
(T0), 12 months post-randomisation (T1-at completion
of intervention) and at 3 months after the end of treat-
ment (15 months post-randomisation) (T2-) (Table 1).
At each time point participants will be asked to repeat
all baseline questionnaires plus provide a fasting blood
sample and anthropometric measurements. 12- and 15-
month follow-up windows will be defined as minus
6 weeks and plus 4 weeks for 12 month, and plus
4 weeks for 15 month follow-up. Data collected outside
these time windows will be recorded but not used for
the main analyses.
Baseline measures:
i. Sociodemographic data; age, gender, self-reported
ethnicity, marital status.
ii. Quality of life: Short Form-36; including mental
health and physical health subscales [43].
iii. Substance use measures: Time Line Follow Back;
[47] Nicotine Dependence Questionnaire; [48,49]
Alcohol Use Disorders Identification Test (AUDIT);
[50] and a urine drug screen.
iv. Biomedical status measures: waist and hip
circumference; height and weight to calculate body
mass index; blood pressure; fasting blood glucose;
insulin (to calculate the homeostasis model
assessment-estimated insulin resistance (HOMA-IR)
index); long term blood glucose control (as
measured by glycated haemoglobin); fasting lipids;
renal and liver function tests and other markers of
cardiovascular risk and inflammation.
v. Lifestyles measures: adapted Dietary Instrument
for Nutrition Education DINE; [51] adapted
International Physical Activity Questionnaire
(IPAQ) [52].
vi. Mental health status: Positive And Negative
Syndrome Scale (PANSS)[53], Global Assessment of
Functioning (GAF)[54], Montgomery Asberg
Depression Rating Scale (MADRS) [55].
vii. Diagnosis; OPCRIT (Operational Criteria checklist)
[56].
viii.Health care: Medical history of diabetes,
cardiovascular disease and cerebrovascular disease;
other past medical history. Family history of diabetes
and related disorders.
ix. Current medications; Composite measure of
compliance scale [57]; Liverpool University
Neuroleptic Side Effect Rating Scale (LUNSERS) [58].
x. Costs: adapted Client Services Receipt Inventory
(CSRI) [59].
Table 1 IMPACT outcome measures at defined timepoints
Measure Baseline 12 months 15 months
SF-36 (Physical and mental health
components)
X X X
Time line follow back X X X
Nicotine dependence
questionnaire
X X X
AUDIT X X X
DINE X X X
IPAQ X X X
Waist/hip circumference ratio X X X
BMI X X X
Blood pressure X X X
Fasting glucose X X X
Insulin resistance X X X
Long term blood glucose control
(HbA1c)
X X X
Lipids X X X
Uric acid X X X
High sensitivity C reactive protein X X X
Urine drug screen X X X
PANSS X X X
GAF X X X
MADRS X X X
OPCRIT X X X
LUNSERS X X X
Age at randomisation X X X
Gender X X X
Ethnicity X X X
Marital status X X X
Current medications X X X
Medical history X X X
Measures of compliance (1–7
scale)
X X X
Variables measured at baseline, 12 months and 15 months follow-up.
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xi. IMPACT Therapy dosage measures: HPI inputs and
Supervision log form.
Sample size
The power analysis is performed for the two subscales
measures, Physical and Mental health components of SF-
36 Quality of Life scale.[43] We have assumed a common
standard deviation of the change scores between baseline
and 12 month follow-up of 10 for the Physical component
score and 12 for the Mental health component score
(based on the QUATRO study [60]), supplemented
with further information sought directly from the study
team (project reference: QLG4-CT-2001-01734, European
Union)) and a cluster size of 4 patients per care coordin-
ator with intraclass correlation of 0.05. Using 80% power,
a 5% alpha level and two-tailed assumptions, a sample size
of 56 care coordinators and 216 patients are needed to de-
tect a clinical significant difference of 5 points in Mental
Health Component change score (Cohen’s d = 0.42), be-
tween two groups and a sample size of 38 care coordina-
tors and 152 patients are needed to detect a clinical
significant difference of 5 points in Physical Component
change score (Cohen’s d = 0.5) between two groups. As-
suming a drop-out rate of 20% of the care-coordinators
and their patients and an additional patient drop-out rate
of 30%, a total sample size of 98 care coordinators and
392 participants are needed for the Mental health score
and 70 care coordinators and 280 participants for the
Physical health score.
Data analysis
The analysis will follow the guidelines of the Consort
statement for clustered randomized trials [45] and rec-
ommendations for the analysis of clustered randomized
trials when presenting and analysing the data.[61,62]
The trial statistician will remain blind until the main
analyses are complete.
Baseline characteristics of the study population will be
summarised separately within each randomised group.
Baseline characteristics will also be presented for drop-
outs and completers within each treatment group.
Intention-to-treat sample
The analysis will be performed on the basis of the
intention-to-treat principle and will utilise all available
follow-up data from all randomised participants. Follow-
up data will be collected for all patients whose care-
coordinator was randomized independent of whether a
care coordinator dropped out or not.
The main statistical analyses will be targeted at esti-
mating the difference in the mean outcomes of Physical
and Mental health components of SF36 [43] at 12 and
15 months follow-up observation time point between
treatment and control group using a mixed effects
model. [63]The outcome variables are assumed to arise
from normal distributions. This will be checked and if
found to be lacking then appropriate transformations
will be applied.
In the linear mixed effects model Physical and Mental
health Component scores respectively, at 12 months and
15 months constitute the dependent variables. “Treat-
ment randomisation group, “time (with two levels, 12
and 15 months post-randomization)”, the interaction be-
tween “treatment group and time”, “Borough”, and the
“baseline values of Physical and Mental Health scores”
are the fixed part of the model. “Care coordinator” will
be included as a random factor in the model to account
for the dependency of the observations within a cluster.
“Time” will be entered as a categorical variable.
It is possible that the treatment effects will vary across
the care coordinators delivering the interventions. We
will therefore also assess an “intervention group x care
coordinator” interaction term. A likelihood ratio test of
the corresponding variance component and information
criteria comparisons will be used to assess if the interac-
tions should be included in the model. Similarly, the
interaction between treatment and time will be assessed.
Should there be evidence for such an interaction then
the relevant terms will be kept in the model. For the
final model, the group difference estimates and associ-
ated confidence intervals will be reported for 12 and
15 months after randomization.
No a priori subgroups were defined in the protocol.
Sensitivity of results to missing data
We expect that for a proportion of patients it will not be
possible to measure outcome scores at 12 and/ or
15 months and that some data will be missing. The de-
scribed mixed model will be fitted using maximum like-
lihood methods that are valid under the missing at
random (MAR) assumption.[64] However, this assump-
tion relates to the variables that are included in the
model. To allow for a variable predicting “missingness”,
this variable needs to be included as either one of the
explanatory or dependent variables of the mixed model.
We will perform three sensitivity analyses for violations
of the assumptions of MAR to assess the sensitivity of
the results to missing outcome data:
In the first sensitivity analysis we will use the method
of multiple imputations.[64] Data handled using multiple
imputation will be imputed 100 or more times, applying
a set seed using the ice package in STATA version 11.0
[65]. In this procedure missing data is filled in using
other information which has been observed on patients.
For our analysis, the imputation model will include all
variables which we believe may contain information
about the missingness mechanism at 12 and 15 months
and must include all variables that will be used in the
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main analysis model [66]. We account for clustering by
including cluster indicators in our imputation model
[67]. Each of these completed datasets can then be
analysed using the proposed statistical modelling and
the estimates from the linear mixed model will be drawn
from the average of analysis of each of the completed
datasets using Rubin’s Rule [64].
Analysis of data where the outcome is incomplete al-
ways requires the untestable assumptions about the
missing data that they are missing at random. We, there-
fore, will perform a second sensitivity analyses to explore
the effect of departures (varied over a plausible range)
from the assumption of missing at random made in the
main analysis as recommended by White et al [68]. For
example, to assess for differential drop-out in patients
between treatment groups a sensitivity analysis would
assume that the cases lost to follow-up have systematic-
ally worse outcome than completers and outcome will
be worse in treatment group and we will assess the effect
of different values on the treatment differences at
12 months.
We also anticipate drop-out of care-coordinators. In a
further sensitivity analysis we will perform the same ana-
lysis as described for the Intent-to treat sample using the
patients whose care coordinator did not drop out. This
analysis assumes that care coordinators drop-out is com-
pletely at random (MCAR) to obtain unbiased results. We
will analyse the reasons for drop-out of care-coordinator
and participants using a qualitative approach which allows
us to assess the validity of this assumption.
Complier average causal effects (CACE)
In addition to the standard intention-to-treat analysis we
will estimate a measure of the treatment impact only for
compliers. Specifically, we will employ complier average
causal effects (CACE), where randomisation indicator is
used as an instrumental variable to evaluate the causal
effect of HPI in the subpopulations that are considered
compliers to treatment. [69]This complier average causal
effect is of scientific and policy interest, because it as-
sesses the intervention effectiveness of the treatment
when it is in fact taken (treatment efficacy).
Economic evaluation
The economic evaluation will be from two perspectives:
health/social care and societal (the latter additionally in-
cludes production losses due to time off work for those
in employment).
To estimate HPI costs, relevant staff will document
resource inputs (care coordinator training/supervision
and intervention sessions with study participants). Other
resource use data will be collected retrospectively by par-
ticipant self-report using specifically designed interviewer-
administered questionnaires at baseline, 12 months (each
for the previous 6 months) and 15 months (previous
3 months). Unit costs will be attached to all resource use
to estimate individual-level total costs.
Costs and outcomes will be described by arm and as-
sessment point but the economic evaluation will focus
on 15-month findings in the form of cost-effectiveness
analyses based on SF-36 mental and physical component
scores and cost-utility analyses based on quality-adjusted
life years (QALYs). QALYs will be calculated by applying
UK general population utility weights to the SF-36 [43]
(via the SF-6D) [70] with adjustment for relevant period
of time and linear interpolation to calculate the area
under the curve.
Costs and QALYs will be reported as mean values per
arm with standard deviations. Differences between arms
will be tested by multi-level modelling to accommodate
cluster randomisation.
Given two cost perspectives and three outcome mea-
sures, there will be 6 cost-outcome combinations to con-
sider. For combinations suggesting one arm having
additional costs alongside improvements in outcomes,
incremental cost-effectiveness ratios (ICERs) will repre-
sent the additional cost per additional unit of outcome.
Uncertainty will be explored using incremental cost-
effectiveness planes and cost-effectiveness acceptability
curves (CEACs) based on the net benefit approach [71].
CEACs will represent the likelihood of the HPI being
cost-effective relative to the control given different mon-
etary values for incremental improvements in SF-36 and
QALY outcomes. CEACs will be based on bootstrapped
(to account for non-normally distributed data) regres-
sions of arm upon net benefits, controlling for clusters.
Sensitivity analyses will explore consequences for cost-
effectiveness/utility results if key assumptions are altered
(e.g. HPI unit costs, imputation for loss of follow-up).
Process analysis
To address the research question of the process evalu-
ation part of this trial and to try and understand the
pathway from therapy to psychological change between
pre-treatment and follow-up, we will carry out media-
tional analyses [72] using the process variables (e.g. ther-
apist alliance) as potential mediators.
Data management
The Clinical Trials Unit based at the Institute of Psychiatry,
KCL will be employed to set up a ‘live’ database on which
researchers will directly input data while assessing partici-
pants at the specified timepoints using the MACRO
system.
Ethics committee approval
Ethical approval for this study was obtained from The Joint
South London and Maudsley and The Institute of Psychiatry
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NHS Research Ethics Committee. Ethical approval was
granted on 17th July 2009 (REC Ref no. 09/H080/41).
Discussion
This paper describes the study protocol for a cluster
randomised trial designed to investigate the effectiveness
and cost-effectiveness of a novel non-pharmacological
health promotion intervention (IMPACT therapy) in
community based patients with SMI. The primary and
secondary outcomes for the study are quality of life
(both physical and mental health), health related behav-
iours, physical health parameters and change in sub-
stance misuse in a population of individuals with SMI.
There is mounting evidence to support the role of
non-pharmacological interventions in improving weight
gain and reducing metabolic risk in SMI. A recent meta-
analysis recommended that studies of behavioural and
health promotion interventions in SMI need to be of
longer duration and with larger sample sizes, as well as
assessing whether any effect is maintained [73]. The
large sample size, long duration of follow up, and the
additional 3 month follow on period to assess the main-
tenance of response will help bridge this gap in the evi-
dence base. That meta-analysis also recommended
measurement of a broad range of cardiometabolic risk
markers and more detailed investigation of mechanisms
and predictors of weight loss. Data collected as part of
this RCT will allow more detailed exploration of these
areas.
The trial is designed to inform real-world practice; it
takes a pragmatic approach, with the intervention being
delivered by the patient’s own care co-ordinator in the
usual community treatment setting, yet maintains high
levels of academic rigour with standardised staff training
in the intervention, random allocation, and effective
blinding. Provision of therapy by the usual care worker
will reduce the incidence of accidental unblinding.
There remains a paucity of evidence based guidance
available to guide clinicians in the treatment of physical
comorbidity in this complex group of individuals with
SMI. The clinical and economic results of this trial will in-
form service planners and clinicians alike about the poten-
tial benefits, costs and cost-effectiveness of IMPACT
therapy, providing evidence as to whether national and
international dissemination is justified.
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